For the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.
Ibrutinib can be safely combined with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, according to a new study presented at the American Society of Hematology 58th Annual Meeting and Exposition, held December 3–6.
Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.
Pembrolizumab has good activity, is safe and well-tolerated, and induces durable responses in cutaneous T-cell lymphomas, according to a study presented at the American Society of Hematology Annual Meeting & Exposition.
Caveolin-1 (CAV1) appears to play an oncogenic role in breast cancer by fostering molecular hubs for signaling, and should be considered a potential target for therapeutic investigation, in particular in triple-negative disease.
Multigene panels can detect significant pathogenic mutations in a proportion of breast cancer patients who have tested negative for BRCA1/2 gene mutations, according to a new study.
High expression of the known tumor promotor TOX3 gene leads to poorer prognosis in breast cancer patients with luminal B disease, according to a new study.
Neratinib Improves Invasive Disease-Free Survival in Centrally Confirmed HER2-Positive Breast Cancer
Neratinib significantly improves invasive disease-free survival (iDFS) in trastuzumab (Herceptin)-treated, early-stage, human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients, with an enhanced treatment effect observed in women with centrally confirmed HER2+ tumors.
More accurate identification of molecular subtyping for breast cancer may be able to identify patients with chemosensitivity to specific therapies, according to a new study.
Aromatase inhibitors can reduce risk of contralateral breast cancer in women who have a BRCA mutation, according to a new study.